drugset / Trial / NCT03154333

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

NCT03154333

Phase 2 Terminated 54 enrolled Castle Creek Pharmaceuticals, LLC
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Epidermolysis bullosa simplex (EBS) is a rare genetic skin disease characterized by fragility of the skin and mucous membranes resulting in painful blisters and erosions after minor trauma. The purpose of this study is to compare the efficacy of diacerein 1% ointment to vehicle ointment when applied once-daily for 8 weeks in subjects with EBS.

Timeline

Start
2017-06-01
Primary completion
2018-10-15
Completion
2018-10-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Diacerein Small molecule 1 % Topical